We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
AREXVY GlaxoSmithKline Australia Pty Ltd
Product name
AREXVY
Accepted date
Apr-2024
Active ingredients
recombinant respiratory syncytial virus pre-fusion F protein
Proposed indication
For the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).
Application type
C (new indication)
Publication date
Apr-2024